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DOI 10.1186/s13071-015-0735-3RESEARCH Open AccessDifferential effect of human ivermectin treatment
on blood feeding Anopheles gambiae and Culex
quinquefasciatus
Yahya A Derua1*, William N Kisinza1 and Paul E Simonsen2Abstract
Background: Widespread and large scale use of ivermectin in humans and domestic animals can have unexpected
effects on non-target organisms. As a search for a possible explanation for an observed longitudinal decline in density
of anopheline vector mosquitoes, but not in Culex quinquefasciatus, in an area of north-eastern Tanzania which has
been exposed to ivermectin mass drug administration, this study assessed and compared the effect of human
ivermectin treatment on blood feeding Anopheles gambiae and Cx. quinquefasciatus.
Methods: Consenting adult volunteers were randomized into two groups to receive either ivermectin or
placebo. Twenty four hours after treatment, one volunteer from each group was concurrently exposed to 50
laboratory reared An. gambiae on one arm and 50 laboratory reared Cx. quinquefasciatus on the other arm for
15–30 minutes. Engorged mosquitoes were maintained on 10% glucose solution for 12 days and observed for
survival and fecundity. The experiment was repeated 15 times.
Results: Two days after the blood meals, nearly half (average 47.7% for the 15 experiments) of the blood fed An.
gambiae in the ivermectin group had died while almost all in the placebo group were alive (97.2%), and the
difference in survival between these two groups continued to widen on the following days. There was no clear
effect of ivermectin on Cx. quinquefasciatus, which had high survival in both ivermectin and placebo group on
day 2 (95.7% and 98.4%, respectively) as well as on the following days. Ivermectin completely inhibited egg
laying in An. gambiae, while egg laying and subsequent development of immature stages appeared normal in
the other three groups.
Conclusion: Blood meals taken on ivermectin treated volunteers significantly reduced survival and halted fecundity of
An. gambiae but had only limited or no effect on Cx. quinquefasciatus. The result suggests that widespread use of
ivermectin may have contributed to the observed decline in density of An. gambiae, without similar decrease in Cx.
quinquefasciatus, in north-eastern Tanzania.
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Ivermectin, a macrocyclic lactone derived as a fermenta-
tion product from the soil bacteria Streptomyces avermi-
litis [1], is widely used globally in human and veterinary
medicine as a drug for treatment and control of nema-
tode and ecto-parasitic infections. It is currently also
used in large scale programs to eliminate human* Correspondence: yahyaathman@yahoo.com
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unless otherwise stated.onchocerciasis and lymphatic filariasis in many countries
in sub-Saharan Africa, through yearly application of
community-wide ivermectin mass drug administration
(MDA) [2]. In concordance with the extensive scale-up
and use of ivermectin in recent years, its potential effect
on non-target organisms, including many species of free-
living arthropods, has been increasingly documented [3].
This includes its effect on dung beetles being exposed to
ivermectin when feeding on faecal matter from treated
cattle, as well as on freshwater stages of insects exposed to
ivermectin excreted into their environment.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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male Anopheles gambiae mosquitoes have a much higher
mortality if they feed on humans shortly after treatment
with ivermectin than if they feed on untreated humans
[4]. Laboratory studies using membrane feeding of adult
mosquitoes have confirmed this effect of ivermectin,
when used in concentrations equaling those found in
treated humans, in female An. gambiae whereas no ef-
fect was seen in female Aedes aegypti [5,6]. In line with
this, field studies have indicated that human MDA with
ivermectin may have resulted in a temporary significant
reduction in malaria transmission, most likely due to its
effect on the anopheline vectors [7-10]. This has led to
the suggestion that human MDA with ivermectin could
be used as a supplement measure for malaria transmis-
sion control [9-12].
In Tanzania, An. gambiae and An. funestus are the
major vectors of human malaria, and these two mos-
quito species together with Cx. quinquefasciatus are also
the vectors of lymphatic filariasis. A longitudinal study
conducted in north-eastern Tanzania has documented a
dramatic decline in anopheline mosquito densities dur-
ing the past decade, whereas no decline has been seen in
densities of Cx. quinquefasciatus [13,14]. The cause of
these changes, which have important implications for
the transmission and control of malaria and lymphatic
filariasis in the area, remains somewhat unclear, and
could not immediately be related to change in rainfall
pattern or major application of mosquito control inter-
ventions [14]. In fact, insecticide treated bed-nets (ITNs)
were only distributed on a large scale after the major de-
cline in anopheline population densities occurred. As
MDA with ivermectin has been widely applied in the
area for control of onchocerciasis and lymphatic filariasis
[13,15], the present study assessed and compared the
survival and fecundity of An. gambiae and Cx. quinque-
fasciatus mosquitoes after taking a blood meal on
humans treated with ivermectin.
Methods
Mosquitoes
An. gambiae sensu stricto (a colony originating from
Kisumu, Kenya) and Cx. quinquefasciatus (a colony ori-
ginating from Arusha, Tanzania) mosquitoes which had
been maintained for several generations at the insectary
of the National Institute for Medical Research, Amani
Research Centre, in Tanga Region of Tanzania, were
used in the feeding experiments. They were raised using
recommended standard mosquito rearing techniques
[16]. Adult mosquitoes for feeding experiments were
kept in cages and supplied with cotton pads soaked in
10% glucose solution until they reached an age of 3 days.
They were then starved for 6–8 hours before being fed
on the human volunteers.Experimental drugs
Ivermectin tablets (Mectzan®, Laboratoires Merck Sharp &
Dohme-Chibret, Paris, France) were generously sup-
plied by the Regional Neglected Tropical Diseases Control
Programme in Tanga. This programme also provided
height guides for estimation of dosage according to proce-
dures used during MDAs (150–200 μg/kg body weight).
Multivitamin tablets (Laboratory & Allied Ltd, Nairobi,
Kenya) were used as placebo at a dose of 2 tablets per
person.
Selection and treatment of volunteers
Amani Research Centre staff and community members
living near the Amani Research Centre premises were
invited to participate in the study. A total of 30 adult
volunteers, who gave written informed consent, were re-
cruited for the feeding experiments. Volunteers were
randomly assigned to either an ivermectin (n = 15) or a
placebo (n = 15) treatment group. This assignment was
blinded to the volunteers, to those who provided them
the drugs as well as to those who handled the mosquito
feeding and subsequently observed mosquito survival.
The volunteers were thereafter arranged in 15 pairs,
each with an ivermectin and a placebo group member,
to participate in 15 mosquito feeding experiments on 15
different days. Each experiment started by requesting the
pair of volunteers to swallow their respective assigned
drug in the evening at 18:00 hours. They were then re-
quested to return 24 hours later for mosquito feeding.
Mosquito feeding and mortality scoring
At the time of mosquito feeding, 50 An. gambiae and 50
Cx. quinquefasciatus maintained in cages were concur-
rently allowed to feed on exposed arms of each volun-
teer for 15 to 30 minutes (until no more mosquitoes
showed interest in feeding on the bait). Each volunteer
was instructed to insert the right arm in the cage
containing 50 An. gambiae and the left arm in the cage
containing 50 Cx. quinquefasciatus mosquitoes. The
mosquito cages were labeled with codes identifying the
feeder, the treatment given and the species of mosquito.
Thus, feeding experiments were carried out with two
volunteers at a time (ivermectin and placebo group) and
repeated 15 times using new volunteers and new batches
of mosquitoes. Following the feeding, unfed mosquitoes
were removed from the cage using an aspirator. Fully
engorged mosquitoes were maintained on 10% glucose
solution (soaked onto cotton wool) and observed for
mortality every 24 hours for 12 days. On each day, dead
mosquitoes were counted and removed from the cages.
The test mosquitoes were provided with egg laying sub-
strate to monitor their egg laying ability three days
(72 hours) after the blood meal. An. gambiae mosquitoes
were provided with a wet filter paper fitted in a Petri-dish
Table 1 Overview of mosquitoes exposed and mosquitoes
that fed in the two treatment groups
Treatment group Mosquito species No. exposed No. fed (%)
Ivermectin An. gambiae 750 732 (97.6)
Cx. quinquefasciatus 750 478 (63.7)
All 1500 1210 (80.7)
Placebo An. gambiae 750 729 (97.1)
Cx. quinquefasciatus 750 469 (62.5)
All 1500 1198 (79.9)
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An. gambiae mosquitoes. For Cx. quinquefasciatus, a plas-
tic larvae-rearing pan containing water was placed in the
cage with survivors of this species. These devices were left
in place for three days and then transferred to a larvae-
rearing room for incubation and egg hatching. Eggs were
not counted. Upon hatching, the offspring were reared to
adult mosquitoes following routine procedures.
Data analysis
Data were entered in Excel and subsequently analyzed
by SPSS. Proportions were compared by Pearson’s Chi-
square test and continuous variables by Student’s t-test.
P-values < 0.05 were considered statistically significant.
Ethics
Ethical approval for this study was obtained from the
Medical Research Coordinating Committee of the Na-
tional Institute for Medical Research, Tanzania (Ref:
NIMR/HQ/R.8a/Vol. IX/1554). Written informed con-
sent was obtained from all volunteers before they partic-
ipated in the study. Mosquito feeding experiments were
conducted using insectary reared mosquitoes free from
any infection. The study coincided with the timing of
ivermectin based MDA in the area, and volunteers who
took ivermectin were informed not to take the ivermec-
tin distributed in the communities in 2013. Volunteers
who took multivitamin were encouraged to participate
in the 2013 MDA. The volunteers were also told that
they would experience minor discomfort and itching
during mosquito feeding, resembling their usual experi-
ence with mosquito bites in north-eastern Tanzania.
Results
A total of 30 adult volunteers (25 males, 5 females; mean
age 32.4 years; age range 19–50 years) were assigned to
either the ivermectin (n = 15) or the placebo (n = 15)
treatment group. Fifteen consecutive mosquito feeding
experiments were conducted. In each experiment, one
volunteer from each treatment group fed An. gambiae
and Cx. quinquefasciatus simultaneously (each volunteer
arm with different species). Of the 1500 An. gambiae
and 1500 Cx. quinquefasciatus exposed to the feeding
baits, 1461 (97.4%) and 947 (63.1%), respectively, fed
(Table 1). Mosquitoes were moreover attracted differ-
ently by individual volunteers such that for An. gambiae
a mean of 48.7 mosquitoes fed (range 36–50) while for
Cx. quinquefasciatus a mean of 31.6 mosquitoes fed
(range 8–50) in the 30 feeding sessions (2 sessions in
each of the 15 experiments). However, there was no sig-
nificant difference in overall percentage of mosquitoes
that fed in the ivermectin or the placebo group, neither
for An. gambiae (97.6% vs. 97.1%, respectively; p = 0.75)nor for Cx. quinquefasciatus (63.7% vs. 62.5%, respect-
ively; p = 0.67).
The mean number (and range) of live blood fed mos-
quitoes that survived in each of the four experimental
groups during the 12 days are shown in Table 2. For An.
gambiae, blood fed mosquitoes died considerably faster
in the ivermectin than the placebo group. Already on
day 2, nearly half of the blood fed An. gambiae in the
ivermectin group had died while those in the placebo
group appeared largely unaffected. The gap between the
two groups in mean number of surviving mosquitoes
widened from day to day, and on day 6 the mean num-
ber was only 10% of starting value for the ivermectin
group while it was 91% for the placebo group. Statistical
analysis showed that from day 2 onwards the mean
number of live mosquitoes was significantly lower in the
ivermectin group than in the placebo group (p < 0.001
for all days). In the later period of the experiments (es-
pecially after day 8) some mortality also became evident
in the placebo group, possibly mainly due to increasing
mosquito age.
By contrast, no clear effect of ivermectin was observed
on the mean number of blood fed Cx. quinquefasciatus
(Table 2), and on none of the experimental days was
there a statistically significant difference between the
mean number in the ivermectin and the placebo group
(p > 0.05 for all days). There was also a gradual but slight
decrease in mean number of mosquitoes in both treat-
ment groups (most noticeable after day 8), which pos-
sibly was mainly due to increasing mosquito age.
As the number of mosquitoes feeding varied between
experiments, the percent survival should rightly be cal-
culated separately for each experiment and group, and
the mean survival in groups then calculated on the basis
of survival in the individual experiments. This has been
done in Table 3, where moreover data have been ex-
cluded from both ivermectin and placebo groups when
the mortality in the placebo group exceeded 20%. This
gives an even more striking impression of the difference
in An. gambiae survival between the ivermectin and the
placebo group, and of the lack of difference between
these groups in Cx. quinquefasciatus. The mean survival
in the four experimental groups until day 8 (when
Table 2 Mean number (range) of live blood fed mosquitoes for the 15 experiments as recorded on each day in the four
experimental groups
Day Mean no. (range) of An. gambiae Mean no. (range) of Cx. quinquefasciatus
Ivermectin group Placebo group p-value* Ivermectin group Placebo group p-value*
0 48.8 (36–50) 48.6 (40–50) NS 31.9 (13–50) 31.3 (8–50) NS
1 45.5 (28–50) 48.3 (40–50) NS 31.1 (11–50) 31.2 (8–50) NS
2 25.4 (9–45) 47.2 (40–50) <0.001 30.7 (11–50) 30.9 (7–50) NS
3 16.7 (0–37) 46.4 (40–50) <0.001 30.1 (11–49) 30.7 (7–50) NS
4 10.4 (0–18) 45.7 (40–50) <0.001 29.9 (11–49) 30.7 (7–50) NS
5 6.5 (0–14) 44.9 (39–49) <0.001 29.5 (11–49) 30.3 (7–50) NS
6 5.0 (0–14) 44.3 (39–49) <0.001 29.1 (10–49) 29.6 (7–50) NS
7 2.9 (0–10) 42.3 (38–49) <0.001 28.9 (10–49) 29.3 (7–50) NS
8 2.4 (0–10) 33.3 (20–49) <0.001 27.9 (10–48) 27.9 (6–50) NS
9 1.7 (0–5) 27.8 (5–43) <0.001 27.5 (9–48) 27.5 (6–50) NS
10 1.5 (0–4) 23.3 (1–39) <0.001 26.5 (9–48) 27.1 (5–50) NS
11 1.3 (0–4) 21.3 (0–36) < 0.001 25.0 (9–48) 26.1 (5–48) NS
12 0.8 (0–2) 16.0 (0–36) < 0.001 20.5 (0–48) 21.1 (0–48) NS
*Student’s t-test; NS = not significant.
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periments) is moreover shown in Figure 1.
Three days after the feeding, a total of 247 and 697
surviving An. gambiae and 447 and 459 surviving Cx.
quinquefasciatus in the ivermectin and placebo groups,
respectively, were provided with egg laying substrates.
None of the An. gambiae in the ivermectin group laid
eggs, although the majority spent long periods on the
laying substrate, and eventually some were recovered
dead on the substrate. Surviving An. gambiae in theTable 3 Mosquito survival on each day of the experiment in t
Day An. gambiae
No. experiments
included
Mean % survival in
ivermectin group*
Mean % survival
in placebo group*
0 15 100.0 100.0
1 15 93.4 99.5
2 15 52.3 97.2
3 15 33.8 95.6
4 15 21.2 94.2
5 15 13.3 92.6
6 15 10.3 91.3
7 13 7.0 87.6
8 6 6.0 86.8
9 2 5.0 88.0
10 1 0.0 80.0
11 1 0.0 80.0
12 1 0.0 80.0
Calculated as mean of % survival in the individual experiments. For each of the two
placebo group exceeded 20%.
*Mean for included experiments.placebo group as well as Cx. quinquefasciatus in both
groups laid eggs. The eggs hatched and larvae were sub-
sequently reared to adult mosquitoes.
Discussion
Ivermectin has a broad spectrum of activity against hel-
minth and ecto-parasite infections and its widespread use
in human and veterinary medicine has been linked with
potential effects on non-target organisms [3]. Ivermectin
based MDA to humans for control and elimination ofhe four groups
Cx. quinquefasciatus
No. experiments
included
Mean % survival in
ivermectin group*
Mean % survival
in placebo group*
15 100.0 100.0
15 97.1 99.9
15 95.7 98.4
15 93.5 97.8
15 92.8 97.8
15 91.7 96.7
13 89.6 95.3
13 88.9 94.9
13 85.5 89.8
13 83.6 88.0
13 80.4 86.4
12 75.1 85.7
9 80.3 86.4
species, results from experiments were excluded when mortality in the
Figure 1 Survival of Anopheles gambiae and Culex quinquefasciatus
after taking a blood meal on human volunteers who had ingested
ivermectin (150–200 μg/kg) or placebo. Graphs show mean of %
survival in the individual experiments for the four groups during
the first 8 days. 15 experiments were carried out, but data were
excluded from both ivermectin and placebo group of the same
mosquito species when the mortality in the placebo group exceeded
20%. Thus, for the two An. gambiae groups, data on days 7 and 8 are
based on 13 and 6 experiments, while for the two Cx. quinquefasciatus
groups, data on days 6, 7 and 8 are all based on 13 experiments (see
also Table 3).
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to reduce survival of An. gambiae mosquitoes and thereby
also to affect malaria transmission [7,8,10]. As a result,
ivermectin has recently been considered a drug with po-
tential in integrated malaria control operations [8,10-12].
MDA with ivermectin is also well known to have a benefi-
cial effect on human infections with ectoparasites, such as
scabies and lice [2]. In north-eastern Tanzania, where iver-
mectin based MDA has been in place for more than a dec-
ade, a significant decline in overall malaria vector density
has been recorded. During the same period, no decline
(rather an increase) in density of Cx. quinquefasciatus was
noted [13,14]. The observed changes could not explicitly
be explained by change in rainfall pattern or mosquito
control interventions. Thus, this study was a sequel of an
effort to indirectly assess whether ivermectin based MDAs
could have contributed to causing the observed changes
in mosquito population densities in the study area.
Using insectary reared An. gambiae and Cx. quinque-
fasciatus, 15 mosquito feeding experiments were con-
ducted to compare the survival and fecundity of these
vectors when fed on human hosts recently treated with
ivermectin or a placebo. The two species of mosquitoes
had different feeding efficiency, with 97.4% and 63.1%,
respectively, taking a blood meal. The lower efficiency of
Cx. quinquefasciatus was probably due to its preference
for bird feeding [17] whereas An. gambiae is known to
be strongly anthropophilic [18]. For both species, the
number of fed mosquitoes moreover varied between thevolunteers. Such differential human attractiveness to
mosquitoes is a common phenomenon [19]. In some of
the experiments, an increase was seen in mortality in
the control group in the later period of the study, prob-
ably due to older age of mosquitoes and/or adverse en-
vironmental factors. For this reason, experimental days
where control group mortality exceeded 20% were ex-
cluded when comparing mosquito survival in the iver-
mectin and control group for the same species.
The study confirmed findings from previous studies,
in that, at a dosage similar to that used in MDAs, iver-
mectin considerably reduced the survival of blood feed-
ing An. gambiae [4,7-12,20]. Thus, after 2 days nearly
half (47.7%) of the blood fed An. gambiae in the iver-
mectin group had died while almost all in the placebo
group were alive, and the difference in survival between
these two groups continued to widen as the experiment
progressed. On the other hand, ivermectin had only
minimal or no effect on the survival of Cx. quinquefas-
ciatus. Chandre and Hougard [21] similarly recorded no
effect on survival of Cx. quinquefasciatus exposed to a
blood meal from humans treated with a therapeutic dose
of ivermectin. In future studies it will be interesting also
to feed mosquitoes on volunteers at different time inter-
vals after ivermectin treatment, to assess the time-course
of the drug effect on the mosquitoes.
In addition to considerably reduce their survival, iver-
mectin in the blood meal caused complete inhibition of
fecundity in the exposed An. gambiae. Thus, among the
An. gambiae that managed to survive for 3 days post
blood meal, none were capable of laying eggs. By con-
trast, the An. gambiae in the placebo group, and the Cx.
quinquefasciatus in both groups laid eggs. The eggs were
incubated, hatched and larvae were successfully reared
to adult mosquitoes. The eggs were not counted, though,
to compare if there was any difference in numbers laid
by Cx. quinquefasciatus in the ivermectin and placebo
group, or in their subsequent development. This would
be worthwhile to investigate further, as in Ae. aegypti
mosquitoes it has been shown that although an ivermec-
tin containing blood meal did not affect survival, it
caused a significant decline in fecundity [22].
The fact that Cx. quinquefasciatus has a slightly lower
feeding capacity on humans, combined with their appar-
ent inherent tolerance to ivermectin in blood meals, put
them at a much reduced risk of being affected by iver-
mectin based MDA when compared to An. gambiae.
These factors, combined with evidence of increasing
proliferation and colonization of more rural areas by Cx.
quinquefasciatus [23,24] and their high level of insecti-
cide tolerance [17,25], might explain the stable density
of this species in the areas with declining anopheline
density in north-eastern Tanzania [14]. The increasing
significance of Cx. quinquefasciatus as a vector of
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pared to the previously most important anopheline vec-
tors [13,26], calls for more research on how to control
this vector.
Conclusions
The study showed that mosquito blood meals taken
from humans recently treated with ivermectin at a dos-
age similar to that used in MDA for control of filarial
infections have a markedly different effect on survival
and fecundity of An. gambiae and Cx. quinquefasciatus.
Thus, while ivermectin treatment considerably reduced
survival and fecundity in the former, no obvious effect
was noted in the latter species. The findings suggest that
the recently observed decline in density of An. gambiae,
but not Cx. quinquefasciatus, in north-eastern Tanzania
might at least partly be attributed to the widespread use
of ivermectin for control of parasitic infections in humans
and domestic animals in the area.
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